- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03688464
Treatment of Nighttime Pruritus in Atopic Dermatitis
August 12, 2023 updated by: University of Nebraska
Efficacy of Melatonin and Diphenhydramine Versus Placebo in Treatment of Nighttime Pruritus in Atopic Dermatitis
This study will look at melatonin vs. first generation antihistamine vs. placebo in improving nighttime itching in children with atopic dermatitis.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This will be a 6 week study to determine the efficacy of melatonin vs. first generation antihistamine vs. placebo in improving nighttime pruritus in children with atopic dermatitis.
Secondary aims will include:
- Determine efficacy of melatonin vs. first generation antihistamine in management of sleep disturbance in children with atopic dermatitis
- Compare differences between treatment groups in disease improvement
- Compare differences between treatment groups in quality of life
Study Type
Interventional
Phase
- Early Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 months to 10 years (Child)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Physician diagnosed eczema covering more than 5% of body surface area
- Ages 2-12 years old
Exclusion Criteria:
- Sleep disorder, including underlying insomnia
- Neuropsychiatric disorder
- Condition that requires use of antihistamines
- On systemic eczema therapy or monoclonal antibody for allergic diseases
- Unable to discontinue other antihistamine use
- Autoimmune disease as melatonin is contraindicated
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Melatonin Treatment
Subjects to receive melatonin 0.1 mg/kg (minimum dose of 1 mg, maximum dose of 5 mg) 30 minutes prior to bedtime (1 mg/ml oral compound suspension) for 4 weeks.
|
Drug to be administered for 4 weeks.
Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
Other Names:
|
Active Comparator: Diphenhydramine Treatment
Subject to receive diphenhydramine 2.5 mg/ml oral liquid, dosed at 1 mg/kg at bedtime for 4 weeks.
|
Drug to be administered for 4 weeks.
Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
Other Names:
|
Placebo Comparator: Placebo
Subjects will receive cherry flavored placebo at bedtime for 4 weeks.
|
Drug to be administered for 4 weeks.
Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
POEM (Patient Oriented Eczema Measure)
Time Frame: 6 weeks
|
This survey is a total of 7 questions that assesses the quality of life of patient's with eczema to determine their disease severity.
The 7 questions are scored out of 4 points.
A higher total score indicates a higher severity of disease.
|
6 weeks
|
EASI score
Time Frame: 6 weeks
|
This tool is also used to assess severity of eczema.
4 different body regions are scored based on the percentage of eczema affecting the area.
The calculations for each region are severity score x area score x known multiplier.
A higher score indicates a higher severity of disease.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
5D Pruritus survey
Time Frame: 6 weeks
|
This survey is a 5 question survey to assess severity of itch in patient's with eczema.
The higher the score the worse the pruritus is and the more it affects the patient on a daily basis.
|
6 weeks
|
ESS-CHAD
Time Frame: 6 weeks
|
This questionnaire is a series of questions that assesses sleepiness.
Patient's can rank the situations based on a 3 point scale, 0 indicating would never doze and 3 indicating a high chance of dozing.
A higher score indicates increased sleepiness.
|
6 weeks
|
Actigraphy
Time Frame: 6 weeks
|
This device is worn on the wrist of a patient like a watch and records sleep-wake cycles.
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kylie Liermann, DO, University of Nebraska
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2018
Primary Completion (Actual)
February 2, 2019
Study Completion (Actual)
February 2, 2019
Study Registration Dates
First Submitted
September 26, 2018
First Submitted That Met QC Criteria
September 26, 2018
First Posted (Actual)
September 28, 2018
Study Record Updates
Last Update Posted (Actual)
August 15, 2023
Last Update Submitted That Met QC Criteria
August 12, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Genetic
- Hypersensitivity
- Skin Manifestations
- Skin Diseases, Eczematous
- Dermatitis
- Eczema
- Pruritus
- Dermatitis, Atopic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Antiemetics
- Gastrointestinal Agents
- Protective Agents
- Dermatologic Agents
- Hypnotics and Sedatives
- Anesthetics, Local
- Antioxidants
- Anti-Allergic Agents
- Sleep Aids, Pharmaceutical
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Melatonin
- Diphenhydramine
- Promethazine
Other Study ID Numbers
- 0197-18-FB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on Melatonin
-
Duquesne UniversityCompleted
-
Peking Union Medical College HospitalCompleted
-
UnivatesAline Patrícia Brietzke; Ana Paula CostellaRecruitingPerimenopausal DisorderBrazil
-
Chinese PLA General HospitalUnknown
-
Assaf-Harofeh Medical CenterNeurim Pharmaceuticals Ltd.UnknownMild Cognitive Impairment (MCI)Israel
-
Qazvin University Of Medical SciencesCompletedPost Partum Haemorrhage in Patients Undergoing Cesarean SectionIran, Islamic Republic of
-
Mayo ClinicRecruitingParkinson Disease | Rapid Eye Movement Sleep Behavior DisorderUnited States
-
Pharmavite LLCKGK Science Inc.Completed
-
Ain Shams UniversityCompletedCerebral Palsy | Growth | Children, Only | MelatoninEgypt
-
Technological Centre of Nutrition and Health, SpainUniversity Rovira i Virgili; Hospital Universitari Sant Joan de Reus; Fundació... and other collaboratorsCompleted